Early Weight Loss With Saxenda Predicts More

Early weight loss in patients taking the newly approved injectable obesity drug liraglutide 3 mg (Saxenda, Novo Nordisk) predicts sustained weight loss with the drug, according to findings from a post hoc analysis of two large randomized trials. More than half (55%) of nondiabetic study participants who lost at least 5% of their total body weight after 4 months on liraglutide (early responders) had a 10% or more weight loss after 56 weeks on the drug, compared to fewer than one in 10 (8%) patients who did not achieve this early weight loss. http://www.medpagetoday.com/Endocrinology/Obesity/55019?xid=nl_mpt_DHE_2015-12-05&eun=g721819d0r